Azilsartan: Current Evidence and Perspectives in Management of Hypertension

Hypertension continues to be global pandemic with huge mortality, morbidity, and financial burden on the health system. Unfortunately, most patients with hypertension would eventually require two or more drugs in combination to achieve their target blood pressure (BP). To this end, emergence of more...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of hypertension Vol. 2019; no. 2019; pp. 1 - 8
Main Authors Pradhan, Akshyaya, Sethi, Rishi, Tiwari, Ashish
Format Journal Article
LanguageEnglish
Published Cairo, Egypt Hindawi Publishing Corporation 2019
Hindawi
John Wiley & Sons, Inc
Hindawi Limited
Subjects
Angiotensin
Angiotensin II receptor blockers
Antihypertensives
Atherosclerosis
Bioavailability
Blood pressure
Cardiovascular disease
Clinical trials
Diuretics
Drug dosages
Enzymes
FDA approval
Heart failure
Hydrochlorothiazide
Hypertension
Morbidity
Mortality
Plasma
R&D
Research & development
Review
Online AccessGet full text

Cover

More Information
Summary:Hypertension continues to be global pandemic with huge mortality, morbidity, and financial burden on the health system. Unfortunately, most patients with hypertension would eventually require two or more drugs in combination to achieve their target blood pressure (BP). To this end, emergence of more potent antihypertensive drugs is a welcome sign. Angiotensin receptor blockers (ARBs) are cornerstones of hypertension management in daily practice. Among all ARBs, azilsartan is proven to be more potent in most of the head-to-head trials till date. Azilsartan is the latest ARB approved for hypertension with greater potency and minimal side effects. This review highlights the role of azilsartan in management of hypertension in the current era.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Academic Editor: Tomohiro Katsuya
ISSN:2090-0384
2090-0392
2090-0392
DOI:10.1155/2019/1824621